Description
HIV AIDS
Latest News
Advertisement
Advertisement
Abstract: Rhinosinusitis affects millions of persons annually and has a marked impact on quality of life and work productivity. Chronic rhinosinusitis (CRS) is characterized by symptoms that last at least 12 weeks. The history and physical examination should include a search for underlying conditions, such as allergic or nonallergic rhinitis and nasal polyposis. An evaluation of underlying immunodeficiency is warranted in certain patients, particularly those with severe or difficult-to-treat disease or other recurrent infections. When radiologic evaluation is indicated, coronal sinus CT scanning is the procedure of choice. While antibiotics are indicated for bacte- rial rhinosinusitis, intranasal corticosteroids represent the mainstay of treatment for CRS and are particularly useful when polyp disease is present. Nasal irrigation with a saline solution can be a very beneficial adjunctive therapy. Depending on coexisting conditions, additional treatments may include antihistamines, leukotriene modifiers, and immunotherapy. (J Respir Dis. 2006;27(9):372-379)
TORONTO -- As better antiretroviral regimens are developed, more patients infected with HIV are succumbing to fatal opportunistic infections that are the hallmark of AIDS.
TORONTO -- Human growth hormone appears to reverse some elements of HIV-treatment related lipodystrophy, researchers reported here.
TORONTO -- HIV therapy introduced in Third World countries should focus on antiretroviral regimens designed for long-term success, investigators emphasized here.
TORONTO -- The bleak early days of the AIDS crisis, when clinicians were grabbing at straws, provided lessons for today, said researchers who reviewed the history of the epidemic -- now in its 25th year -- at the 16th International AIDS Conference here.
TORONTO -- The target of most HIV therapy is the virus itself, but researchers said here that another approach -- blocking cells' entry points and locking the virus out -- is also starting to show promise.
TORONTO -- An extensively drug-resistant virulent strain of tuberculosis (XDR-TB) killed 52 of 53 patients who were co-infected with HIV during an outbreak in a rural South African hospital, researchers reported here.
TORONTO -- This Special Report from Zach Wise, a contributing photographer for MedPage Today, provides a multimedia portrayal of the activities at the 16th Annual International AIDS Conference here.
TORONTO -- An intravaginal ring, similar to those used to deliver contraceptives and hormonal agents, is a promising way to deliver anti-HIV microbicides, investigators reported here.
TORONTO -- An investigational pediatric version of a recently approved HIV drug is safe and well-tolerated at two different doses and appears to be effective, researchers said here.
TORONTO -- This Special Report from Zach Wise, a contributing videographer for MedPage Today, provides a multimedia portrayal of the activities at the 16th Annual International AIDS Conference here.
TORONTO -- The transmission of drug-resistant HIV appears to be stabilizing, at least in Europe, but about 9% of newly infected HIV patients still carry a virus that carries resistance mutations to one of the three main classes of anti-retroviral medications.
TORONTO -- This Special Report from Zach Wise, a contributing videographer for MedPage Today, provides a multimedia portrayal of the activities at the 16th Annual International AIDS Conference here.
TORONTO -- HIV patients are 18 times more likely than the general population to become infected with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and the rate appears to be increasing.
TORONTO -- HIV-positive patients are at a small but increased risk of cardiovascular disease from antiretroviral therapy, investigators reported here.
TORONTO -- Increased cholesterol and triglycerides in HIV-infected children being treated with highly active antiretroviral therapy (HAART) can be markedly reduced by switching regimens, researchers reported here.
TORONTO -- Even in HIV-infected patients who have tried and failed several drug regimens, the goal should still be to reduce the virus to undetectable levels, according to guidelines presented here.
TORONTO -- This Special Report from Zach Wise, a contributing videographer for MedPage Today, provides a multimedia portrayal of the activities at the 16th Annual International AIDS Conference here.
TORONTO -- Once patients have controlled HIV with a standard drug cocktail, treatment with a "boosted" protease inhibitor may be all they need to keep the virus at bay.
TORONTO -- HIV patients ages 50 and over do a better job controlling the virus but may need more help managing adverse effects and comorbidities.
CHAPEL HILL, N.C. -- Of U.S. adolescents in the general population, 3.5% have exchanged sex for money or drugs, and two-thirds of these youths were boys, researchers reported.
LOS ANGELES -- Unmarried life may impinge on life expectancy, according to researchers here.
GENEVA -- The notion of HIV-treatment interruption -- consigned not long ago to the ash heap of failed ideas -- should be revisited, said investigators here.
LONDON -- Improvements in highly active anti-retroviral therapy (HAART) has resulted in lower viral loads and higher immune cell counts but not a decline in mortality or progression to AIDS.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections
2
4 FDA Decisions for Primary Care to Know from October 2026
3
The Future of HIV PrEP and One Step to Take Tomorrow
4
Why a Negative Endometrial Biopsy May Not End the Abnormal Bleeding Workup
5